The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy

On 2 June 2020, a marketing authorisation valid through the European Union (EU) was issued for encorafenib in combination with cetuximab in adult patients with metastatic colorectal carcinoma (mCRC) with the BRAFV600E mutation who had received prior systemic therapy. Encorafenib plus cetuximab was e...

Descripción completa

Detalles Bibliográficos
Autores principales: Trullas, A., Delgado, J., Koenig, J., Fuerstenau, U., Dedorath, J., Hausmann, S., Stock, T., Enzmann, H., Pignatti, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809377/
https://www.ncbi.nlm.nih.gov/pubmed/33422765
http://dx.doi.org/10.1016/j.esmoop.2020.100031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809377/
https://www.ncbi.nlm.nih.gov/pubmed/33422765
http://dx.doi.org/10.1016/j.esmoop.2020.100031

Ejemplares similares